Inhibrx Inc.

Inhibrx Inc.

World Rank (Jan-05-2024)
6,046
Market Cap (Jan-05-2024)
1.809 Billion USD
World Rank (Jul-30-2023)
7,998
World Rank (Jan-07-2022)
8,138
Market Cap (Jan-07-2022)
1.294 Billion USD
World Rank (Jan-01-2021)
7,075
Market Cap (Jan-01-2021)
1.243 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
INBX
Market Cap (Mar-08-2026)
1.01
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
7,125 Million USD
Annual Net Income in USD
-81 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
150 Million USD
Total Liabilities in USD
98 Million USD
Total Equity in USD
52 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
INHIBRX, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Inhibrx is a Clinical Stage Biotechnology company developed a diverse pipeline of therapeutic candidates specifically designed to leverage the power of core sdAb (single-domain antibody) platform and protein engineering expertise. The company annual revenue is 34.1 million USD and 80 employees as on 2020. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share